scholarly journals High Grade Sarcoma with Chondrosarcomatous Differentiation in Primary Uterine Leiomyosarcoma; A Rare Case and Review of Literature

2021 ◽  
pp. 100905
Author(s):  
Qandeel Sadiq ◽  
Farhan Khan
2018 ◽  
Vol 04 (01) ◽  
Author(s):  
Ali Imran Kucuk Belma Kocer ◽  
Gupse Turan ◽  
Gulsah Kaygusuz ◽  
Serpil Dizbay Sak ◽  
Fuldem Mutlu

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S1353-S1354
Author(s):  
Rajiv Mallipudi ◽  
Rikhil Kochhar ◽  
Christopher DiGiorgio ◽  
Swami Nathan ◽  
Michael Itidiare

Chirurgia ◽  
2019 ◽  
Vol 32 (5) ◽  
Author(s):  
Damiano Bisogni ◽  
Riccardo Naspetti ◽  
Luca Talamucci ◽  
Andrea Valeri ◽  
Roberto Manetti

2021 ◽  
Author(s):  
James Janopaul‐Naylor ◽  
Kirk R. Kanter ◽  
Stella Flampouri ◽  
Vivi Nguyen ◽  
Thomas A. Olson ◽  
...  

Author(s):  
Arunkumar Kamalakaran ◽  
Balaji Jayaraman ◽  
Supraja Raghavendran ◽  
Rohini Thirunavukkarasu ◽  
Mariammal Ayyappan ◽  
...  

2016 ◽  
Author(s):  
Dharma Ram

Introduction: Uterine sarcoma accounts for nearly 3% of all uterine malignancies. They have 4 major pathology includes endometrial stromal sarcoma high grade, ESS low grade, uterine leiomyosarcoma (uLMS) and undifferentiated uterine sarcoma (UUS). Recent WHO classification 2014, recognizes low grade ESS and high grade ESS as distinct entity. They differ from endometrial carcinoma in their aggressive nature and poor prognosis. We review our database and found total 44 eligible patient treated at our institute. Materials and Methods: Its retrospective analysis of computer based database of our institute from January 2009 to December 2015. We analyzed demographic, pathological, treatment and survival data. Results: Total 44 patient treated for uterine sarcoma at our institute. Among these 16 were operated at our institute during study period. Here we reporting results of operated patients at our institute. The histological diagnosis LMS (5/16), ESS-L (4/16), MMMT (3/16), UUS (3/16) and ESS-H (1/16). Stage distribution was stage I, (6/16) stage II, (5/16) stage III, (3/16) stage IV, (0/16) and unknown stage (2/16). Two patients underwent completion surgery for outside myomectomy. The adjuvant treatment was CT in 3/16, CT with RT in 7/16, HT in 4/16 and one lost to follow up with one was put on observation. Median follow up is 30 month with 14 patients alive and one lost to follow up. At last follow up 4 patients alive with metastatic disease and 10 patients alive with no evidence of disease. Conclusion: Uterine sarcoma are uncommon disease with


Sign in / Sign up

Export Citation Format

Share Document